Medical Devices and Surgical Robotics

Sector Definition and Market Structure

Section 201(h) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(h)) defines a device as an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent or related article intended for the diagnosis, cure, mitigation, treatment or prevention of disease, or intended to affect the structure or any function of the body. FDA has established classifications for approximately 1,700 generic types of devices and grouped them into 16 medical specialties it calls panels, according to its Classify Your Medical Device page.

Section 513 of the Act (21 U.S.C. 360c) assigns every device type to one of three classes: Class I under general controls, Class II under special controls, and Class III under premarket approval. FDA states that classification is risk based, with Class I holding the lowest-risk devices and Class III the highest. In vitro diagnostics meet the same statutory definition, and LeverVenture underwrites them within its Diagnostics and Precision Medicine sector.

Surgical Robotics

FDA describes robotically-assisted surgical (RAS) devices as one type of computer-assisted surgical system, a category that also covers systems for pre-operative planning and surgical navigation. FDA states that a RAS device is not actually a robot, because it cannot perform surgery without direct human control. A typical system comprises a surgeon console, a bedside cart with three or four hinged arms and an endoscope, and a separate cart of supporting hardware, used with multiple instruments and accessories, per the same FDA page.

FDA has cleared RAS devices for laparoscopic procedures in general, cardiac, colorectal, gynecologic, head and neck, thoracic and urologic surgery, and its page, current as of September 24, 2026, states that it has not authorized any RAS device specifically for the prevention or treatment of cancer. In September 2026, FDA issued draft guidance on premarket submissions for robotically-assisted surgical devices, defined as teleoperated, software-controlled systems that assist practitioners in positioning and controlling surgical instruments in open, minimally invasive or endoluminal procedures. The draft is not for implementation, and its comment period closes on November 24, 2026.

The architecture sets the underwriting. Because each system is used with multiple instruments and accessories, we underwrite a surgical robotics company on what an installed system earns across the procedures performed with it, and we treat utilization per installed system, and the number of surgeons trained to sustain it, as the operating evidence of the business.

Authorization Routes

A 510(k) under 21 CFR Part 807, Subpart E, shows that a device is substantially equivalent to a legally marketed predicate, and FDA states that the determination is usually made within 90 days. A De Novo request under 21 CFR Part 860, Subpart D, classifies a novel device with no predicate into Class I or II, and FDA states that the device may then serve as a predicate for later 510(k) submissions.

Premarket approval under 21 CFR Part 814 applies to Class III devices, and FDA calls it the most stringent device marketing application, with approval resting on sufficient valid scientific evidence that the device is safe and effective for its intended use. Clinical investigations of a device's safety and effectiveness run under the investigational device exemption rules in 21 CFR Part 812.

The Breakthrough Devices Program is voluntary and covers devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions. FDA reports that, as of June 30, 2026, it had granted 1,320 Breakthrough Device designations and recorded 210 marketing authorizations for designated devices.

Investment Criteria and Underwriting

LeverVenture invests at the growth stage, in the passage between venture capital, which underwrites whether a technology can work, and private equity, which underwrites whether a working business can be optimized. Our posture is a minority position, and we look for management teams that would take an operator on the cap table over a board observer. A device company must meet all seven conditions on the thesis page: market, position, evidence, unit economics, management, exit logic and impact. A company that misses one is a decline with the reason written down.

Every opportunity is scored on the LeverRating, whose six dimensions are Team, Market, Product, Traction, Financial and Thesis fit. For a device, the six expand to ten, so that regulatory position, clinical evidence, reimbursement and freedom to operate each carry their own weight. Both rulers are run, and a rating that holds under only one of them is reported as unresolved. Under ROI², the second return is named at entry as access to care, healthy life extended or system cost removed, and a claim of system cost removed holds only if a payer or provider is measurably better off.

Quality System and Postmarket Record

The Quality Management System Regulation became effective on February 2, 2026, amending 21 CFR Part 820 to incorporate ISO 13485:2016 by reference and, in FDA's words, to require risk management specifically. On the same date FDA began inspecting manufacturers under Compliance Program 7382.850. Under 21 CFR Part 803, a manufacturer reports deaths, serious injuries and malfunctions within 30 calendar days of becoming aware of them, and certain events within 5 work days. We read the complaint, medical device report and corrective-action history as evidence of how the product performs in the field.

Coding, Coverage and Payment

CMS states that coding is distinct from coverage and that a new code does not automatically imply coverage by any payer. Under the Hospital Outpatient Prospective Payment System, services are paid through Ambulatory Payment Classifications, and the comprehensive classification policy packages supporting items into a primary service. Transitional pass-through payment under 42 CFR 419.66 lasts at least 2 but not more than 3 years. For an inpatient case whose costs exceed the full DRG payment, the new technology add-on payment under 42 CFR 412.88 is generally the lesser of 65 percent of the technology's cost or 65 percent of the amount by which the cost of the case exceeds the standard DRG payment.

CMS finalized Transitional Coverage for Emerging Technologies in a notice published August 12, 2024. On August 11, 2026, it published a proposed procedural notice for the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, with comments due October 13, 2026, and the notice states that TCET is paused for new candidates upon its publication. As of October 10, 2026, RAPID has not been finalized. The notice limits RAPID to certain Class II and Class III Breakthrough-designated devices that are still at the IDE pre-submission stage and excludes in vitro diagnostics, so the reimbursement plan now has to be settled before the pivotal study is designed.

Crossing Sectors

The strongest device companies rarely sit in one sector. Crossing sectors is the thesis. A healthcare-driven company that is also deep tech in its engineering, that is also digital in its data, or that carries a clean tech dimension, with an artificial intelligence layer that makes it work, is the company we look for, and we underwrite the whole company as a single object.

Artificial Intelligence as the Accelerant

Artificial intelligence is an accelerant inside this sector, not a separate one. FDA's list of AI-enabled medical devices, current as of September 4, 2026, carries 1,614 entries: 1,553 cleared through 510(k), 40 granted through De Novo and 21 approved through premarket approval, and FDA states that the list is not comprehensive. FDA's final guidance on predetermined change control plans for AI-enabled device software functions is dated August 2025, and under section 515C of the Act (21 U.S.C. 360e-4) a change consistent with an authorized plan needs no new 510(k) or premarket approval supplement.

In diligence we test whether the planned model changes sit inside an authorized plan, who holds the rights to the training data, and whether the quality system controls the model with the same discipline it applies to hardware.

Reference Entries

• Software as a Medical Device (SaMD)how software with a medical purpose is defined, excluded or authorized through a 510(k), De Novo request or premarket approval.
• AI Diligence in Life Sciencesthe evidence-based assessment of whether a company's artificial intelligence claims are supported by its data, validation, regulatory record and quality system.
• Management Services Organizationthe company that provides administrative and management services to a physician-owned practice, relevant where devices are sold through ambulatory surgery centers and physician practices.
• Growth Equityminority capital with little or no leverage for established, fast-growing companies, between late-stage venture capital and buyouts.
• Operating Partneran executive with line-management experience who helps portfolio companies improve their operations.

Related Analysis

• Life Sciences and HealthcareHow Medtech and Surgical Robotics Founders Should Approach Growth Capitalthe FDA pathway and the reimbursement pathway that growth investors ask device founders to answer first.
• Life Sciences and HealthcareFDA Digital Health Guidance: Regulatory Clarity Accelerates Innovationhow a predetermined change control plan lets an AI-enabled device keep improving after clearance, and what that changes in diligence.
• Growth EquityGrowth Equity in Life Sciences: 2026 Market Studythe capital market for life sciences and healthcare, the five sectors, and where the mid-market gap sits.

Governing Authority and Sources

• 21 U.S.C. 321(h), FD&C Act Section 201(h), definition of device
• 21 U.S.C. 360c, FD&C Act Section 513, classification of devices
• FDA, Classify Your Medical Device
• FDA, Computer-Assisted Surgical Systems (current as of September 24, 2026)
• FDA, Robotically-Assisted Surgical Devices: Premarket Submissions, draft guidance (September 2026)
• 21 CFR Part 807, Establishment Registration, Device Listing and Premarket Notification
• FDA, Premarket Notification 510(k)
• 21 CFR Part 860, Medical Device Classification Procedures, Subpart D, De Novo Classification
• FDA, De Novo Classification Request
• 21 CFR Part 814, Premarket Approval of Medical Devices
• FDA, Premarket Approval (PMA)
• 21 CFR Part 812, Investigational Device Exemptions
• FDA, Breakthrough Devices Program (data as of June 30, 2026)
• 21 CFR Part 820, Quality Management System Regulation (effective February 2, 2026)
• FDA, Quality Management System Regulation (QMSR)
• 21 CFR Part 803, Medical Device Reporting
• FDA, Mandatory Reporting Requirements: Manufacturers, Importers and Device User Facilities
• CMS, Guide for Medical Technology Companies: Coding
• CMS, Guide for Medical Technology Companies: Hospital Outpatient Prospective Payment System
• 42 CFR 419.66, Transitional pass-through payments for medical devices
• 42 CFR 412.88, Additional payment for new medical service or technology
• CMS, Transitional Coverage for Emerging Technologies, final notice, 89 FR 65724 (August 12, 2024)
• CMS, Final Notice: Transitional Coverage for Emerging Technologies (CMS-3421-FN), fact sheet (2024)
• CMS, Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway, notice with comment, 91 FR 51710 (August 11, 2026)
• 21 U.S.C. 360e-4, FD&C Act Section 515C, predetermined change control plans
• FDA, Artificial Intelligence-Enabled Medical Devices list (current as of September 4, 2026)
• FDA, Predetermined Change Control Plan for AI-Enabled Device Software Functions, final guidance (August 2025)